Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pierard, D.
Right arrow Articles by Lauwers, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pierard, D.
Right arrow Articles by Lauwers, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 41, 443-450, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy

REVIEWS

Comparative in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology units. Belgian Multicentre Study Group

D Pierard, K Emmerechts and S Lauwers
Department of Microbiology, Akademisch Ziekenhuis Vrije Universiteit Brussels, Belgium. labomicro@az.vub.ac.be

The susceptibility of 389 Enterobacteriaceae, 231 other Gram-negative bacilli (including 150 Pseudomonas aeruginosa) and 233 Gram-positive organisms was determined by the NCCLS reference microdilution technique against cefpirome and other antibiotics. Cefpirome and cefepime were the most active compounds against Enterobacteriaceae, including potentially beta-lactamase-inducible species. The MIC90 of cefpirome against potentially inducible and non-inducible species of Enterobacteriaceae was 2 mg/L and 0.5 mg/L, respectively. Ceftazidime, cefpirome and cefepime had similar activity against P. aeruginosa, with MIC90s of 64 mg/L, 64 mg/L and 32 mg/L, respectively. Cefpirome and cefepime had similar activity against Gram-positive cocci, with MIC90s of 1 mg/L and 2 mg/L, respectively, against oxacillin-susceptible Staphylococcus aureus and 64 mg/L and 128 mg/L, respectively, against Enterococcus spp.; both had an MIC90 of 1 mg/L against Streptococcus pneumoniae. This study shows that fourth-generation cephalosporins, such as cefpirome, could be useful in haematology/oncology units and, in particular, ICUs where high resistance rates are observed.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
R. Sauermann, G. Delle-Karth, C. Marsik, I. Steiner, M. Zeitlinger, B. X. Mayer-Helm, A. Georgopoulos, M. Muller, and C. Joukhadar
Pharmacokinetics and Pharmacodynamics of Cefpirome in Subcutaneous Adipose Tissue of Septic Patients
Antimicrob. Agents Chemother., February 1, 2005; 49(2): 650 - 655.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Van Eldere
Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections
J. Antimicrob. Chemother., February 1, 2003; 51(2): 347 - 352.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Carricajo, N. Fonsale, A. C. Vautrin, and G. Aubert
In vitro activity of {beta}-lactams against gentamicin-susceptible and gentamicin-resistant Staphylococcus aureus
J. Antimicrob. Chemother., November 1, 2000; 46(5): 856 - 858.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.